Trials / Recruiting
RecruitingNCT05851677
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disitamab vedotin | recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2027-03-01
- Completion
- 2027-08-01
- First posted
- 2023-05-10
- Last updated
- 2025-09-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05851677. Inclusion in this directory is not an endorsement.